Trial · NCT00552396
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 0.0003 mg/kg | 0 | Number of participants with DLT | ||
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 0.003 mg/kg | 0 | Number of participants with DLT | ||
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 0.015 mg/kg | 0 | Number of participants with DLT | ||
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 0.075 mg/kg | 1 | Number of participants with DLT | ||
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 0.3mg/kg | 0 | Number of participants with DLT | ||
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 1mg/kg | 0 | Number of participants with DLT | ||
| Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment | IPH2101 3 mg/kg | 0 | Number of participants with DLT | ||
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 0.0003 mg/kg | 0 | Geometric Coefficient of Variation 0 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 0.003 mg/kg | 45.8 | Geometric Coefficient of Variation 41.3 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 0.015 mg/kg | 316 | Geometric Coefficient of Variation 53.8 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 0.075 mg/kg | 1620 | Geometric Coefficient of Variation 38.4 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 0.3 mg/kg | 4510 | Geometric Coefficient of Variation 30.9 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 1 mg/kg | 24800 | Geometric Coefficient of Variation 25.5 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration | IPH2101 3 mg/kg | 55200 | Geometric Coefficient of Variation 31.7 | ng/mL | |
| Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration | IPH2101 0.0003 mg/kg | 0 | Geometric Coefficient of Variation 0 | ng*hours/ml | |
| Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration | IPH2101 0.003 mg/kg | 808 | Geometric Coefficient of Variation 49.7 | ng*hours/ml | |
| Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration | IPH2101 0.015 mg/kg | 16593 | Geometric Coefficient of Variation 273.3 | ng*hours/ml | |
| Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration | IPH2101 0.075 mg/kg | 161811 | Geometric Coefficient of Variation 61.5 | ng*hours/ml | |
| Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration | IPH2101 0.3mg/kg | 596308 | Geometric Coefficient of Variation 0 | ng*hours/ml | |
| Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration | IPH2101 1 mg/kg | 4331537 | Geometric Coefficient of Variation 60.7 | ng*hours/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00552396/results